While AMPLIFY (RR 0.31, 95% CI 0.17–0.55) and EINSTEIN-PE (HR 0.49, 95% CI 0.31–0.79) trials found a significantly lower risk of major bleeding, the results of the corresponding emulations showed the same direction but did not reach statistical significance.
← all excerpts
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism.
1
—
—